Related references
Note: Only part of the references are listed.Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Heliang Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Immune receptor inhibition through enforced phosphatase recruitment
Ricardo A. Fernandes et al.
NATURE (2020)
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li et al.
GASTROENTEROLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Hongnan Mo et al.
BRITISH JOURNAL OF CANCER (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development
Meina Liang et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
Roberto Bellucci et al.
ONCOIMMUNOLOGY (2015)
Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Selma Pennacchietti et al.
CANCER RESEARCH (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Ryohei Katayama et al.
CANCER RESEARCH (2013)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
Pottayil Sasikumar et al.
Journal for ImmunoTherapy of Cancer (2013)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
Giovanni Pacchiana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells
Mahdia Benkhoucha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Structural basis for agonism and antagonism of hepatocyte growth factor
W. David Tolbert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions
Kunio Matsumoto et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
RMF Cardoso et al.
IMMUNITY (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Adoptive-cell-transfer therapy for the treatment of patients with cancer
ME Dudley et al.
NATURE REVIEWS CANCER (2003)
Engineered antibodies
Peter J. Hudson et al.
NATURE MEDICINE (2003)
Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V-L domain of the scFv-0 (V-L-V-H) molecule is primarily responsible for formation of a tetramer-trimer equilibrium
O Dolezal et al.
PROTEIN ENGINEERING (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments:: a clinical phase I/II study
JL Casey et al.
BRITISH JOURNAL OF CANCER (2002)
HLA class I antigen abnormalities and immune escape by malignant cells
B Seliger et al.
SEMINARS IN CANCER BIOLOGY (2002)
Share Paper
